Studies how guselkumab affects immune cells in scalp psoriasis lesions
Tests guselkumab's effect on immune cells in scalp psoriasis lesions.
Plain-language title generated from the registry record
Registry title: Immune Spatial Features of Guselkumab Cutaneous Response
Key facts
- Where
- San Francisco, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of California San FranciscoSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT05858632
- Record updated
- 4 June 2026
- Original description
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.Read full original descriptionShow less
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Exclusion: tuberculosis or other active serious infection; active systemic malignancy; Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data; taking systemic immunosuppressives in the last 4 weeks; pregnancy; severe immunodeficiency (either from genetic or infectious causes); breast-feeding; Males who are trying to conceive; -.